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ABSTRACT
Reduction of the risk of asthma attacks is a major goal 
of current asthma management. We propose to derive 
a risk scale predicting asthma attacks based on the 
blood eosinophil count and exhaled nitric oxide (FeNO). 
Biomarker- stratified trial- level attack rates were extracted 
and pooled from the control arms of the Novel START, 
CAPTAIN, QUEST, Benralizumab Phase 2b, PATHWAY, 
STRATOS 1–2 and DREAM trials (n=3051). These were 
used to derive rate ratios and the predicted asthma 
attack rate for different patient groups. The resultant 
prototype risk scale shows potential to predict asthma 
attacks, which may be prevented by anti- inflammatory 
treatment.
INTRODUCTION
Assessment and reduction of the risk of attacks 
are a major goal of asthma management.1 
However, our ability to do this is limited for 
several reasons. First, the extent to which the 
risk associated with clinical characteristics is 
independent of the inflammatory phenotype 
has not been defined. Second, some acknowl-
edged risk factors are difficult to identify and/or 
modify, for example, non- adherence and obesity, 
respectively. Third, some parameters can be 
modified independent of an effect on asthma 
attacks; for example, symptom burden improves 
following bronchodilator monotherapy without 
an effect on asthma attacks.2 These limitations 
mean that a precise estimation of the risk of 
asthma attacks and the likely benefit of treat-
ment is not possible.
Recently, five analyses of clinical trials across 
the spectrum of asthma severity have assessed the 
independent relationship between blood eosin-
ophils, fractional exhaled nitric oxide (FeNO) 
and the risk of asthma attacks.3–7 Collectively, 
these studies show that the prognostic impor-
tance of these biomarkers is similar in strength 
and additive to the independent risk seen with 
more established risk factors such as a history 
of an attack in the last year and Global Initiative 
for Asthma (GINA) treatment step.8 In four out 
of the five studies, the prognostic value of blood 
eosinophils and FeNO was additive.3 5–7
These findings suggest that the blood eosin-
ophil count and FeNO could form the basis of a 
useful risk scale analogous to those that have had a 
large impact in cardiovascular medicine.9 We have 
explored this hypothesis by developing a prototype 
risk scale.
METHODS
We designed a scale presenting the modifiable risk 
of asthma attacks associated with blood eosino-
phils and FeNO on the background of the unmod-
ifiable risk associated with GINA treatment step, 
a recent history of an asthma attack and the pres-
ence of less modifiable risk factors. Asthma attacks 
were defined as episodes of acute asthma requiring 
treatment with systemic steroids ≥3 days and/or 
hospitalisation.
We used control arm data3–7 from the trials 
described in the supplementary table (see online 
supplemental file 1) to derive frequency- weighted 
rate ratios of asthma attacks by biomarker combi-
nations using established cut points for blood 
eosinophil counts and FeNO (table 1). Indi-
vidual trial rate ratios were calculated as follows: 
[(absolute asthma attack rate for subgroup 
1)×(frequency n1)] ÷ [(frequency- weighted mean 
for the remaining subgroups 2–9)×(Σ(n2 to 9))]. 
Aggregate rate ratios (rightmost column of table) 
were calculated as frequency- weighted means of 
the individual trial’s rate ratios for each biomarker 
combination. In effect, an aggregate rate ratio 
is a mean fold change in the asthma attack rate 
for patients with that biomarker combination 
compared with others.
We used asthma attack rates from a US popula-
tion study involving 222 817 patients to derive a 
predicted asthma attack rate by GINA step.8 We 
further stratified by a history of an asthma attack 
in the last year (which we assumed increased risk by 
a factor of 2.8)8 and the presence of two or more 
additional potential risk factors (which we assumed 
increased risk by a factor of 1.3). Our estimate of 
the additional risk associated with two or more 
additional potential risk factors was based on the 
difference in asthma attack rates in the CAPTAIN 
population,5 who had persistent symptoms and 
airflow obstruction, compared with the Novel 
START population,4 who had neither.
To populate each cell of the prototype risk scale, 
the reference rate for GINA treatment steps 1, 2, 
3, 4 and 5 was multiplied by the appropriate risk 
pertaining to that group for example, the figure’s 
rightmost column’s rates are calculated as [aggre-
gate biomarker- stratified rate ratio] × [GINA treat-
ment step- specific attack rate] × 2.8 × 1.3.
A frequency- weighted intraclass correlation 
coefficient (two- way mixed model for absolute 
agreement of single measures) and 95% CIs were 
computed between the predicted and observed 
asthma attack rates using the derivation trials in 
SPSS V.27.
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The resulting prototype risk scale is shown in the figure 1: each 
cell represents the predicted annual asthma attack rate for a 
given scenario if treatment is not changed. The predicted asthma 
attack rates range from 0.06 to 2.60 per year; they are compa-
rable to observed attack rates in the derivation trial control 
patients (intraclass correlation coefficient: 0.83 (95% CI 0.78 
to 0.86)).
DISCUSSION
We designed a prototype risk scale based on trial- level data that 
shows potential to predict asthma attacks which may be modi-
fied by anti- inflammatory treatment. As is the case with cardi-
ovascular risk, the relative risk associated with biomarkers was 
consistent across populations, but the absolute risk conferred by 
type 2 airway inflammation was greater in a population at higher 
background risk.
The fact that blood eosinophils and FeNO provide addi-
tive prognostic information is predictable, as both biomarkers 
provide different and complementary mechanistic information: 
FeNO reflects airway type 2 activity and the chemotactic pull to 
the airways, while blood eosinophils reflect the systemic pool of 
available effector cells and circulating interleukin 5.10 In contrast, 
symptom scores do not correlate with airway inflammation nor 
with airflow limitation10 and do not reliably predict exacerba-
tions when the inflammatory phenotype is considered.11
An important feature of the prototype risk scale is that it 
centres attention on biomarkers that are not only closely asso-
ciated with the mechanism of asthma attacks but are also easily 
modified with therapy directed against this mechanism. For 
example, the excess risk of asthma attacks associated with the 
highest biomarker combination compared with the lowest was 
effectively removed by low- dose inhaled corticosteroids (ICS) in 
mild asthma,4 an increased dosage of ICS in moderate asthma5 
and biologics in severe asthma.3 In many cases, this reduction in 
risk is associated with a proportionate reduction in biomarkers.
We emphasise that the proposed risk scale is a prototype and 
several assumptions have been made in its derivation. First, there 
were some inconsistencies in the relationship between FeNO and 
the risk of asthma attacks in the mild asthma population,4 which 
likely reflect the small sample sizes. However, a difference in the 
mechanism of asthma attacks or a relatively greater prognostic 
value of FeNO in ICS- treated patients cannot be excluded. 
Larger studies are required to investigate these possibilities. 
Second, we categorised risk factors, and since the independent 
risk conferred by these risk factors over and above that associ-
ated with type 2 biomarkers is unknown, we derived the multi-
plier for having ≥2 risk factors by comparing the Novel START4 
and CAPTAIN5 populations. The resultant multiplier of 1.3 
suggests that the independent impact of these factors is modest, 
but further work is needed to confirm this. Third, although the 
biomarker- stratified rate ratios were adjusted for each other, we 
concede that the other covariates were not perfectly adjusted 
for one another. Fourth, the prototype features categories rather 
than the absolute values of blood eosinophils, FeNO and clinical 
risk factors. We did this as this was the only data available to us. 
It also allowed us to tabulate risk across the spectrum of patients 
and biomarkers in an accessible way. This approach has been 
very successful in cardiovascular risk reduction, but we acknowl-
edge that there may be better ways of representing the contin-
uous risk associated with these factors.
We speculate that a risk scale based on this prototype could 
facilitate better treatment decisions by doctors and patients by 
providing a framework for a preventive, treatable, trait- based 
management. This hypothesis needs to be tested, and it is also 
important that the scale is refined using individual patient data 
from large and well- characterised populations.
Correction notice This article has been corrected since it was published Online 
First. The abstract has been modified.
Figure 1 Prototype asthma attack risk scale. Numbers in each cell are predicted annual asthma attack rates for patients over the age of 12 if 
treatment is not changed. An asthma attack is an episode of acute asthma requiring treatment with systemic steroids ≥3 days and/or hospitalisation. 
The blood eosinophil count is contemporaneous or the highest result in the last 12 months; fractional exhaled nitric oxide level is contemporaneous. 
*Risk factors are defined by the Global Initiative for Asthma (GINA) guidelines1: poor symptom control (Asthma Control Questionnaire score ≥1.5), 
low lung function (forced expiratory volume in 1 second <80% predicted), adherence issues, reliever overuse (>200 dose of salbutamol cannister/
month), intubation or intensive care unit admission for asthma previously, comorbidities (one of chronic rhinosinusitis, obesity and psychiatric disease) 
and environmental exposures (one of smoking, allergen and pollution).
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